View Filing Data

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2014	Nov. 12, 2014
Document and Entity Information
Entity Registrant Name	OptimizeRx Corp
Entity Central Index Key	0001448431
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Type	10-Q
Document Period End Date	Sep. 30, 2014
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	Q3
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		23,404,819

Balance Sheets (Unaudited) - USD ($)	Sep. 30, 2014	Dec. 31, 2013
Current Assets
Cash and cash equivalents	$ 3,260,094	$ 1,118,243
Accounts receivable	1,614,732	1,566,964
Prepaid expenses	48,043	11,771
Total Current Assets	4,922,869	2,696,978
Property and equipment, net	13,436	15,057
Other Assets
Patent rights, net	940,509	885,950
Web development costs, net	493,704	404,986
Security deposit	5,049	5,049
Total Other Assets	1,439,262	1,295,985
TOTAL ASSETS	6,375,567	4,008,020
Current Liabilities
Accounts payable - trade	91,265	188,739
Accounts payable - related party	570,000	570,000
Accrued expenses	7,850	12,000
Revenue share payable	853,410	1,193,661
Deferred revenue		4,252
Total Liabilities	1,522,525	1,968,652
Stockholders' Equity
Common stock, $.001 par value, 500,000,000 shares authorized, 23,362,377 and 14,773,496 shares issued and outstanding, respectively	23,362	14,773
Preferred stock, $.001 par value, 10,000,000 shares authorized, 0 and 65 shares issued and outstanding, respectively
Stock warrants	2,153,295	18,148,049
Additional paid-in-capital	28,398,825	8,726,708
Deferred stock compensation	(5,910)	(233,942)
Accumulated deficit	(25,716,530)	(24,616,220)
Total Stockholders' Equity	4,853,042	2,039,368
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 6,375,567	$ 4,008,020

Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Sep. 30, 2014	Dec. 31, 2013
Statement of Financial Position [Abstract]
Common stock par value	$ 0.001	$ 0.001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	23,362,377	14,773,496
Common stock, shares outstanding	23,362,377	14,773,496
Preferred Stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	65
Preferred stock, shares outstanding	0	65

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Income Statement [Abstract]
NET REVENUE	$ 1,620,215	$ 1,373,029	$ 4,391,775	$ 3,146,406
COST OF SALES	858,898	529,134	1,897,757	1,264,059
GROSS MARGIN	761,317	843,895	2,494,018	1,882,347
OPERATING EXPENSES	1,155,933	985,504	3,594,961	2,272,239
LOSS FROM OPERATIONS	(394,616)	(141,609)	(1,100,943)	(389,892)
OTHER INCOME (EXPENSE)
Interest income	302	82	633	176
TOTAL OTHER INCOME (EXPENSE)	302	82	633	176
LOSS BEFORE PROVISION FOR INCOME TAXES	(394,314)	(141,527)	(1,100,310)	(389,716)
PROVISION FOR INCOME TAXES
NET LOSS	$ (394,314)	$ (141,527)	$ (1,100,310)	$ (389,716)
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING
BASIC AND DILUTED	23,362,377	14,227,713	21,089,514	14,201,373
NET LOSS PER SHARE
BASIC AND DILUTED	$ (0.02)	$ (0.01)	$ (0.05)	$ (0.03)

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss for the period	$ (1,100,310)	$ (389,716)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation and amortization	182,403	144,562
Stock and options issued for services	1,118,952	310,823
Changes in:
Accounts receivable	(47,768)	(532,109)
Prepaid expenses	(36,272)	41,822
Accounts payable	(97,474)	119,760
Revenue share payable	(340,251)	649,825
Accrued expenses	(4,150)	(6,000)
Deferred revenue	(4,252)	(35,980)
NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES	(329,122)	302,987
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment	(2,694)
Patent rights	(103,930)	(38,278)
Website site development costs	(217,435)	(62,280)
NET CASH USED IN INVESTING ACTIVITIES	(324,059)	(100,558)
CASH FLOWS FROM FINANCING ACTIVITIES:
Issuance of common stock	10,000,000
Equity issuance costs	(1,204,968)
Purchase of common and preferred stock and warrants	(6,000,000)
NET CASH PROVIDED BY FINANCING ACTIVITIES	2,795,032
NET INCREASE IN CASH AND CASH EQUIVALENTS	2,141,851	202,429
CASH AND CASH EQUIVALENTS - BEGINNING OF PERIOD	1,118,243	284,263
CASH AND CASH EQUIVALENTS - END OF PERIOD	3,260,094	486,692
SUPPLEMENTAL CASH FLOW INFORMATION:
Cash paid for interest
Cash paid for income taxes

Nature of Business and Basis of Presentation

9 Months Ended

Sep. 30, 2014

Nature of Business and Basis of Presentation [Abstract]

NATURE OF BUSINESS AND BASIS OF PRESENTATION

NOTE 1 – NATURE OF BUSINESS AND BASIS OF PRESENTATION

OptimizeRx Corporation, is a technology solution company focused on the health care industry. Its objective is to bring better access to better care by leveraging its proprietary technology to provide on demand savings and support within physicians and patients web based platforms, including Electronic Health Records and Patient Portals. Initially defined as a marketing and advertising company through its consumer website, OptimizeRx.com, the Company is maturing as a technology solutions provider through its direct to physician solution, SampleMD. SampleMD allows physicians to automatically display and distribute sample vouchers and/or co-pay coupons electronically within the ePrescription platform to pharmacies on behalf of their patients. The SampleMD solution can either sit on the doctor’s desktop or can be integrated into the ePrescribing or Electronic Medical Records applications.

OptimizeRx solutions provide health care institutions with an alternative option to the traditional hassles and issues associated with storing and managing physical drug samples and pre-printed coupons and it provides better access and affordability to patients to improve affordability, adherence and outcomes. In turn, OptimizeRx provides pharmaceutical manufacturers with both direct to consumer and direct to physician channels for more efficiently communicating and promoting their products and savings.

The consolidated financial statements for the three and nine month periods ended September 30, 2014 and 2013 have been prepared by us without audit pursuant to the rules and regulations of the Securities and Exchange Commission. In the opinion of management, all adjustments necessary to present fairly our financial position, results of operations, and cash flows as of September 30, 2014 and 2013, and for the periods then ended, have been made. Those adjustments consist of normal and recurring adjustments. The consolidated balance sheet as of December 31, 2013, has been derived from the audited consolidated balance sheet as of that date.

Certain information and note disclosures normally included in our annual financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted. These consolidated financial statements should be read in conjunction with a reading of the financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2013, as filed with the U.S. Securities and Exchange Commission.

The results of operations for the three and nine month periods ended September 30, 2014, are not necessarily indicative of the results to be expected for the full year. Certain reclassifications have been made in the prior period’s consolidated financial statements to conform to the current period’s presentation.

Stockholders Equity

9 Months Ended

Sep. 30, 2014

Stockholders Equity [Abstract]

STOCKHOLDERS EQUITY

NOTE 2 – STOCKHOLDERS EQUITY

In March 2014, the Company entered into a securities purchase agreement, pursuant to which the Company sold 8,333,333 shares of the Company’s common stock for $1.20 per share, or gross proceeds of $10,000,000.

Placement agents in the offering received commissions equal to approximately 9.7% of gross proceeds, for an aggregate commission of approximately $970,000, including reimbursements for their reasonable out of pocket expenses. Placement agents also received warrants to purchase up to 804,139 shares of the Company's common stock with an exercise price of $1.20 per share and a term of 5 years. The warrants were valued at $1,110,211, have been recorded as equity issuance costs, and were registered on a registration statement dated May 28, 2014. In addition to the warrants to placement agents, the Company also paid cash bonuses of $240,000 to three executive officers, issued 200,000 shares to three executive officers, and issued 150,000 shares to a consultant, in connection with the equity raise. The stock was valued based on the fair market value on the grant date, which was $630,000 in total. These amounts have been recorded as equity issuance costs, resulting in total equity issuance costs of $2.95 million.

The Company used the net proceeds of the offering to exercise the securities redemption option agreement, as amended, with Vicis Capital Master Fund that provided the Company with an option to purchase all of the outstanding shares and derivative securities held by Vicis for total payment of $6,000,000. The shares and derivative securities included the Series A Convertible Preferred Stock, Series B Convertible Preferred Stock, Common Stock, and warrants to purchase shares of common stock held by Vicis in the Company. The balance of the net proceeds will be used for working capital purposes.

In January 2014, an executive officer exercised 500,000 stock warrants using the cashless exercise feature included in the warrants. In exchange for the 500,000 warrants, 410,348 shares of common stock were issued.

In February 2014, the Company granted 337,500 shares of common stock, half of which vested immediately and half of which vested in August 2014, to two executive officers as bonuses based on their efforts to recapitalize the company to secure approximately $3 million in working capital while reducing fully diluted shares by approximately 7 million shares. Stock-based compensation related to these bonuses was $570,375 for the nine months ended September 30, 2014.

During the nine months ended September 30, 2014, the Company issued 54,000 shares of common stock to consultants in connection with investor relations services. These shares were valued based on the fair market value on the date of grant, which resulted in expense totaling $82,300.

No shares of common stock were issued in the nine months September 30, 2013.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph d
-Article 4

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Article 4

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

+ Details

Share Based Payments - Options

9 Months Ended

Sep. 30, 2014

Share Based Payments - Options [Abstract]

SHARE BASED PAYMENTS - OPTIONS

NOTE 3 – SHARE BASED PAYMENTS – OPTIONS

We use the fair value method to account for stock based compensation. We recorded $282,995 and $30,005 in compensation expense in the periods ended September 30, 2014 and 2013, respectively, related to options issued under our stock-based incentive compensation plan. This includes expense related to both options issued and committed in the current year, and options issued in prior years for which the requisite service period for those options includes the current year. The fair value of these instruments was calculated using the Black-Scholes option pricing model. Information related to the assumptions used in this model is set forth in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2013. Assumptions for options issued in the current year approximated the same assumptions, with estimated lives ranging from 3.5 to 5 years.

Contingencies

9 Months Ended

Sep. 30, 2014

Contingencies [Abstract]

CONTINGENCIES

NOTE 4 – CONTINGENCIES

Litigation

In September 2014, we were able to favorably resolve litigation related a default judgment granted against the Company’s predecessor in the action Milton Wilpon et al. v. Continental Capital Corporation, C-289-06, Superior Court of New Jersey. The Court held that Plaintiffs failed to obtain an award against the Company’s predecessor in an arbitration before the AAA as required by the Settlement Agreement and further failed to establish that they properly served the Summons and Complaint upon the Company’s alleged predecessor. The Court held, therefore, that it did not have jurisdiction over the action and declined to consider other issues presented by the case, including the Company’s arguments contesting the merits of Plaintiffs’ alleged claims against the Company’s predecessor. The Court directed the Company to prepare an order reflecting the Court’s holding and the Company prepared such order and filed it with the Court. The Company filed a draft order vacating the Default Judgment, dismissing the Plaintiffs’ claims against the Company and dismissing the Company’s counterclaims and third-party claims. The Court signed the Order on September 22, 2014 and the date for appeal has passed.

Restatement

9 Months Ended

Sep. 30, 2014

Restatement [Abstract]

RESTATEMENT

NOTE 5 – RESTATEMENT

The Company restated its financial statements to change the way it accounts for revenue share expense. The full impact of the restatement was reflected in the December 31, 2013 financial statements at the end of the year. The tables below reflect the impact on the 2013 three and nine month periods reflected in this report.

The restated Consolidated Balance Sheet, Consolidated Statement of Operations and Consolidated Statement of Cash Flows for the periods ended September 30, 2013 is as follows:

Nine months ended September 30, 2013
Financial Statement	Line Item	Corrected			Previously Stated
Income statement	Cost of Sales	$	1,264,059		$	614,234
Income statement	Income (Loss) from operations	$	(389,892	)	$	259,933
Income statement	Income (loss) before income taxes	$	(389,716	)	$	260,109
Income statement	Net income (loss)	$	(389,716	)	$	260,109
Statement of cash flows	Net income (loss)	$	(389,716	)	$	260,109
Statement of cash flows	Increase in revenue share payable	$	649,825		$	0

Three months ended September 30, 2013
Financial Statement	Line Item	Corrected			Previously Stated
Income statement	Cost of Sales	$	529,134		$	376,831
Income statement	Income from operations	$	(141,609	)	$	10,694
Income statement	Income before provision for income taxes	$	(141,527	)	$	10,776
Income statement	Net income	$	(141,527	)	$	10,776

Subsequent Events

9 Months Ended

Sep. 30, 2014

Subsequent Events [Abstract]

SUBSEQUENT EVENTS

NOTE 6 – SUBSEQUENT EVENTS

In October 2014, we issued 35,417 shares of common stock to a former consultant in connection with the cashless exercise of 50,000 warrants with an exercise price of $0.35 per share.

We also issued 7,065 shares of common stock to outside directors of the Company in connection with their compensation as Directors. The grant was valued at the fair market value at the date of grant of $8,478 and accrued as of September 30, 2014.

Restatement (Tables)

9 Months Ended

Sep. 30, 2014

Restatement [Abstract]

Schedule of restatement

Nine months ended September 30, 2013
Financial Statement	Line Item	Corrected			Previously Stated
Income statement	Cost of Sales	$	1,264,059		$	614,234
Income statement	Income (Loss) from operations	$	(389,892	)	$	259,933
Income statement	Income (loss) before income taxes	$	(389,716	)	$	260,109
Income statement	Net income (loss)	$	(389,716	)	$	260,109
Statement of cash flows	Net income (loss)	$	(389,716	)	$	260,109
Statement of cash flows	Increase in revenue share payable	$	649,825		$	0

Three months ended September 30, 2013
Financial Statement	Line Item	Corrected			Previously Stated
Income statement	Cost of Sales	$	529,134		$	376,831
Income statement	Income from operations	$	(141,609	)	$	10,694
Income statement	Income before provision for income taxes	$	(141,527	)	$	10,776
Income statement	Net income	$	(141,527	)	$	10,776

Stockholders Equity (Details) - USD ($)	1 Months Ended		9 Months Ended
Stockholders Equity (Details) - USD ($)	Mar. 31, 2014	Jan. 31, 2014	Sep. 30, 2014
Class of Stock [Line Items]
Common stock issued for equity issuance costs			$ 630,000
Employee bonus, Share			$ 337,500
Employee bonus, Value			570,375
Additional working capital			$ 3,000,000
Fully diluted shares			7,000,000
Stock issued for services			$ 82,300
Stock issued for services, shares			54,000
Equity issuance cost			$ 2,950,000
Securities Purchase Agreement [Member]
Class of Stock [Line Items]
Sale of comman stock shares	8,333,333
Sale of common stock value	$ 10,000,000
Sale of stock price per share	$ 1.20
Placement Agents [Member]
Class of Stock [Line Items]
Commissions percentage	9.70%
Commissions	$ 970,000
Purchase of warrants	804,139
Warrants, Value	$ 1,110,211
Three Officers [Member]
Class of Stock [Line Items]
Employee Bonus	$ 240,000
Shares, Issued	200,000
Consultant [Member]
Class of Stock [Line Items]
Shares, Issued	150,000
Vicis [Member]
Class of Stock [Line Items]
Debt redemption, amount	$ 6,000,000
Officer [Member]
Class of Stock [Line Items]
Shares, Issued		410,348
Warrants exercised, number of shares		500,000

Share Based Payments - Options (Details) - USD ($)	9 Months Ended
Share Based Payments - Options (Details) - USD ($)	Sep. 30, 2014	Sep. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share Based Compensation Expense	$ 282,995	$ 30,005
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Estimated lives rang	3 years 6 months
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Estimated lives rang	5 years

Restatement (Details) - USD ($)	3 Months Ended		9 Months Ended
Restatement (Details) - USD ($)	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Class of Stock [Line Items]
Income (Loss) from operations	$ (394,616)	$ (141,609)	$ (1,100,943)	$ (389,892)
Income (loss) before income taxes	(394,314)	(141,527)	(1,100,310)	(389,716)
NET LOSS	$ (394,314)	(141,527)	(1,100,310)	(389,716)
Net income (loss) Increase in revenue			(1,100,310)	(389,716)
Increase in revenue share payable			$ 340,251	(649,825)
Correction
Class of Stock [Line Items]
Cost of Sales		529,134		1,264,059
Income (Loss) from operations		(141,609)		(389,892)
Income (loss) before income taxes		(141,527)		(389,716)
NET LOSS		(141,527)		(389,716)
Net income (loss) Increase in revenue				(389,716)
Increase in revenue share payable				649,825
Previously Stated
Class of Stock [Line Items]
Cost of Sales		376,831		614,234
Income (Loss) from operations		10,694		259,333
Income (loss) before income taxes		10,776		260,109
NET LOSS		$ 10,776		260,109
Net income (loss) Increase in revenue				260,109
Increase in revenue share payable				$ 0

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Subsequent Events (Details) - USD ($)	1 Months Ended	9 Months Ended
Subsequent Events (Details) - USD ($)	Oct. 31, 2014	Sep. 30, 2014
Director [Member]
Subsequent Event [Line Items]
Common stock Issued shares		7,065
Fair market value of grant		$ 8,478
Subsequent Event [Member]
Subsequent Event [Line Items]
Stock issued for services, shares	35,417
Warrants exercised, number of shares	50,000
Warrants exercise price per share	$ 0.35